Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

04-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The KEYNOTE-146/Study 111 trial

Chung-Han Lee reports the final analysis of KEYNOTE-146/Study 111 trial of lenvatinib plus pembrolizumab in metastatic clear-cell renal cell carcinoma after immune checkpoint inhibitor therapy (4:57).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

30-01-2020 | Renal cell carcinoma | News

Lenvatinib plus pembrolizumab shows promise for RCC and other solid tumors

08-08-2017 | Non-small-cell lung cancer | At a glance | Article

At a glance: The KEYNOTE lung cancer trials
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits